Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Therapy for Comorbid MDD and AUD
NCT07405606Phase 2Recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), alcohol use disorder (AUD), sponsored by Center for Addiction and Mental Health. Started Mar 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07405606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405606.